Walleye Capital’s Metagenomi Therapeutics MGX Stock Holding History

Walleye Capital’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-71,266	Closed	-$169K	–	5228
2025 Q3	$169K	Buy	+71,266	New	+$145K	﹤0.01%	3422

Other funds holding MGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's MGX Position: Q4 2025 in Review

Walleye Capital sold out of Metagenomi Therapeutics (MGX) in Q4 2025, closing a stake of 71,266 shares — an estimated $169K sold.

Walleye Capital first reported a position in MGX in Q3 2025 and held it in 1 quarter. The position peaked at $169K in Q3 2025. 56 funds tracked by Wall St. Rank hold MGX as of Q4 2025.

Walleye Capital reported no remaining Metagenomi Therapeutics position as of Q4 2025 after selling out during the quarter.
Walleye Capital sold 71,266 Metagenomi Therapeutics shares in Q4 2025, an estimated $169K.
Walleye Capital first reported a position in Metagenomi Therapeutics in Q3 2025 and held it in 1 quarter.
Walleye Capital's Metagenomi Therapeutics position peaked at $169K in Q3 2025.
56 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.